IL110325A0 - Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof - Google Patents

Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Info

Publication number
IL110325A0
IL110325A0 IL11032594A IL11032594A IL110325A0 IL 110325 A0 IL110325 A0 IL 110325A0 IL 11032594 A IL11032594 A IL 11032594A IL 11032594 A IL11032594 A IL 11032594A IL 110325 A0 IL110325 A0 IL 110325A0
Authority
IL
Israel
Prior art keywords
wortmannin
phosphatidylinositol
analogs
kinase
inhibition
Prior art date
Application number
IL11032594A
Other languages
English (en)
Original Assignee
Eli Lilley And Company
Univ Arizona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilley And Company, Univ Arizona filed Critical Eli Lilley And Company
Publication of IL110325A0 publication Critical patent/IL110325A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Furan Compounds (AREA)
IL11032594A 1993-07-19 1994-07-14 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof IL110325A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/094,279 US5378725A (en) 1993-07-19 1993-07-19 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Publications (1)

Publication Number Publication Date
IL110325A0 true IL110325A0 (en) 1994-10-21

Family

ID=22244209

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11032594A IL110325A0 (en) 1993-07-19 1994-07-14 Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof

Country Status (16)

Country Link
US (1) US5378725A (member.php)
EP (1) EP0635268A1 (member.php)
JP (1) JPH0753370A (member.php)
KR (1) KR950002755A (member.php)
CN (1) CN1111127A (member.php)
AU (1) AU678831B2 (member.php)
CA (1) CA2128046A1 (member.php)
CZ (1) CZ283806B6 (member.php)
HU (1) HUT67667A (member.php)
IL (1) IL110325A0 (member.php)
NO (1) NO942641L (member.php)
PH (1) PH30794A (member.php)
PL (1) PL304317A1 (member.php)
RU (1) RU94026082A (member.php)
TW (1) TW287102B (member.php)
ZA (1) ZA945103B (member.php)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5468773A (en) * 1993-08-25 1995-11-21 Eli Lilly And Company Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs
US5504103A (en) * 1993-08-25 1996-04-02 Eli Lilly And Company Inhibition of phosphatidylinositol 3-kinase with 17 β-hydroxywortmannin and analogs thereof
US7863429B2 (en) * 1995-12-21 2011-01-04 Qlt Inc. Treatment of inflammatory diseases including psoriasis
US5910417A (en) * 1996-05-31 1999-06-08 National Jewish Center For Immunology And Respiratory Medicine Regulation of cytokine production in a hematopoietic cell
US7670767B1 (en) * 1997-01-16 2010-03-02 The Regents Of The University Of California Genetic alterations associated with cancer
EP2311495B1 (en) * 1998-03-24 2014-09-24 Chugai Seiyaku Kabushiki Kaisha Vascularization inhibitors
US6413773B1 (en) * 1998-06-01 2002-07-02 The Regents Of The University Of California Phosphatidylinositol 3-kinase inhibitors as stimulators of endocrine differentiation
BR9914465A (pt) * 1998-09-29 2001-10-09 Gamida Cell Ltd Métodos para controlar a proliferação e a diferenciação de células-tronco e células progenitoras e uma composição farmacêutica para induzir a diferenciação em uma população de células
US8124630B2 (en) * 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE556713T1 (de) * 1999-01-13 2012-05-15 Bayer Healthcare Llc Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US6566081B1 (en) 1999-10-06 2003-05-20 The Brigham And Women's Hospital, Inc. Methods of identifying a compound which modulates the non-transcriptional non-map-kinase induced effects of steroid hormones
US6667300B2 (en) * 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
EP1289472A4 (en) * 2000-05-30 2004-09-08 Advanced Res & Tech Inst COMPOSITIONS AND METHODS FOR IDENTIFYING SUBSTANCES THAT MODULE THE PTEN FUNCTION AND THE PI-3 KINASE WAYS
AU2002258798A1 (en) * 2001-04-13 2002-10-28 Children's Hospital Medical Center Methods for the treatment of hepatic disorders
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
GB0119863D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
GB0119865D0 (en) 2001-08-14 2001-10-10 Cancer Res Campaign Tech DNA-PK inhibitors
US6703414B2 (en) * 2001-09-14 2004-03-09 Arizona Board Of Regents On Behalf Of The University Of Arizona Device and method for treating restenosis
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
IL152904A0 (en) * 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
AU2003209116A1 (en) * 2002-02-11 2003-09-04 Bayer Pharmaceuticals Corporation Aryl ureas with angiogenesis inhibiting activity
US7049313B2 (en) 2002-02-25 2006-05-23 Kudos Pharmaceuticals Ltd. ATM inhibitors
CA2491555C (en) * 2002-07-10 2012-09-11 Massachusetts Institute Of Technology Solid-phase and solution-phase synthesis of glycosylphosphatidylinositol glycans
US20050054097A1 (en) * 2002-11-17 2005-03-10 Tony Peled EX-VIVO expansion of hematopoietic system cell populations in mononuclear cell cultures
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
GB0304632D0 (en) * 2003-02-28 2003-04-02 Proxara Biotechnology Ltd Method
JP2006521813A (ja) * 2003-03-07 2006-09-28 ガミダ セル リミテッド Ｐｉ３−キナーゼの調節剤を用いた再生可能な幹細胞集団の拡大
AU2004232308A1 (en) * 2003-04-23 2004-11-04 Wyeth Holdings Corporation PEG-wortmannin conjugates
PT1636585E (pt) * 2003-05-20 2008-03-27 Bayer Pharmaceuticals Corp Diarilureias com actividade inibidora de cinase
IL161903A0 (en) * 2003-07-17 2005-11-20 Gamida Cell Ltd Ex vivo progenitor and stem cell expansion for usein the treatment of disease of endodermally- deri ved organs
PL1663978T3 (pl) * 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
KR20060066722A (ko) 2003-08-13 2006-06-16 쿠도스 파마슈티칼스 리미티드 아미노피론 및 ａｔｍ억제제로서의 이의 용도
WO2005016349A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
JP2007537291A (ja) 2004-05-13 2007-12-20 イコス・コーポレイション ヒトホスファチジルイノシトール３−キナーゼデルタの阻害剤としてのキナゾリノン
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
EP1799812A4 (en) * 2004-09-16 2009-09-09 Gamida Cell Ltd EX VIVO CULTIVATION METHODS OF STEM CELLS AND PRECURSOR BY CO-CULTURE WITH MESENCHYMAL CELLS
AU2005286329A1 (en) 2004-09-20 2006-03-30 Cancer Research Technology Limited DNA-PK inhibitors
US7666901B2 (en) * 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN1875959B (zh) * 2004-10-14 2010-05-12 孔庆忠 一种抗癌药物组合物
CN100369632C (zh) * 2004-10-14 2008-02-20 孔庆忠 抗癌药物组合物
CN101115747A (zh) 2005-02-09 2008-01-30 库多斯药物有限公司 Atm抑制剂
WO2006089106A2 (en) * 2005-02-17 2006-08-24 Icos Corporation Phosphoinositide 3-kinase inhibitors for inhibiting leukocyte accumulation
AR054438A1 (es) 2005-04-15 2007-06-27 Kudos Pharm Ltd Inhibidores de adn -pk
EP1886138A4 (en) * 2005-05-11 2009-04-15 Genetic Technologies Ltd METHODS FOR ENRICHING FETAL CELLS
AU2006251428A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
JP2007063205A (ja) * 2005-08-31 2007-03-15 Japan Science & Technology Agency 神経因性疼痛治療剤
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
US20080199441A1 (en) * 2006-11-09 2008-08-21 Tony Peled Use of ex-vivo cultured hematopoietic cells for treatment of peripheral vascular diseases
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20100109416A1 (en) * 2008-11-03 2010-05-06 Jones Margaret L Adjustable safety harness
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN104042618B (zh) 2008-11-13 2018-02-16 吉利德卡利斯托加公司 恶性血液病的治疗
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
KR20120002995A (ko) 2009-03-24 2012-01-09 길리아드 칼리스토가 엘엘씨 ２―퓨리닐―３―톨릴―퀴나졸리논 유도체의 회전장애 이성질체 및 사용 방법
PT2421536E (pt) * 2009-04-20 2015-10-20 Gilead Calistoga Llc Métodos de tratamento para tumores sólidos
MX2012000817A (es) 2009-07-21 2012-05-08 Gilead Calistoga Llc Tratamiento para desordenes del higado con inhibidores pi3k.
BRPI1107182B1 (pt) * 2011-12-29 2022-03-08 Fundação De Amparo À Pesquisa Do Estado De Minas Gerais - Fapemig Composições farmacêuticas contendo ang-(1-7) ou outro agonista do receptor mas em combinação com inibidores de pi3k/akt para tratamento terapêutico anticâncer
CN104204193B (zh) 2012-02-13 2016-10-26 加米达细胞有限公司 间充质干细胞的培养
MD20140100A2 (ro) 2012-03-05 2015-01-31 Gilead Calistoga Llc Forme polimorfe ale (S)-2-(1-(9H-purin-6-ilamino)propil)-5-fluoro-3-fenilchinazolin-4(3H)-onei
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
WO2015095605A1 (en) 2013-12-20 2015-06-25 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
NZ720867A (en) 2013-12-20 2018-01-26 Gilead Calistoga Llc Process methods for phosphatidylinositol 3-kinase inhibitors
US11021467B2 (en) 2014-06-13 2021-06-01 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CN104774239B (zh) * 2015-03-13 2017-01-04 暨南大学 多节孢绿胶霉素类化合物及其用途
CN107058137B (zh) * 2017-06-14 2020-02-07 海正药业(杭州)有限公司 一种渥曼青霉及其生产渥曼青霉素的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3668222A (en) * 1969-05-14 1972-06-06 Sandoz Ltd 11-desacetoxy-wortmannin
US4988682A (en) * 1989-02-03 1991-01-29 University Of Pittsburgh Myo-inositol analogs and method for their use
JPH0328948A (ja) * 1989-06-27 1991-02-07 Nec Corp 入出力制御装置の動作状態情報収集方式

Also Published As

Publication number Publication date
HU9402128D0 (en) 1994-09-28
PH30794A (en) 1997-10-17
CZ169294A3 (en) 1995-02-15
NO942641D0 (no) 1994-07-14
CZ283806B6 (cs) 1998-06-17
RU94026082A (ru) 1996-05-20
JPH0753370A (ja) 1995-02-28
NO942641L (no) 1995-01-20
AU678831B2 (en) 1997-06-12
AU6754094A (en) 1995-01-27
ZA945103B (en) 1996-03-27
CA2128046A1 (en) 1995-01-20
HUT67667A (en) 1995-04-28
CN1111127A (zh) 1995-11-08
KR950002755A (ko) 1995-02-16
US5378725A (en) 1995-01-03
EP0635268A1 (en) 1995-01-25
PL304317A1 (en) 1995-01-23
TW287102B (member.php) 1996-10-01

Similar Documents

Publication Publication Date Title
IL110325A0 (en) Inhibition of phosphatidylinositol 3-kinase with wortmannin and analogs thereof
HU9202085D0 (en) Derivatives of 7-isoindolinyl-quinolone and of naphthyridone-carboxylic acid
HU9303237D0 (en) Determination of prodrugs metabolizable bythe liver and therapeutic use thereof
PL308553A1 (en) Inhibitors of farnesil-protein transferase
HU9303251D0 (en) Novel derivatives of thiopyranopyrrole and preparation thereof
AU631201B2 (en) Corrosion inhibitor and method of use
EP0371667A3 (en) Inhibition of reservoir scale
EP0420489A3 (en) Compensation of lithographic and etch proximity effects
HU893412D0 (en) Inhibitors of interleucin-1
AU8551191A (en) Inhibition of scale
HU9600241D0 (en) Mutable composition and methods of use thereof
AU8074294A (en) Rapid synthesis and use of 18f-fluoromisonidazole and analogs
HU9400478D0 (en) Process for the preparation of beta-phenylisoserine derivatives and use thereof
AU1680292A (en) Pharmaceutical combination for the treatment of prostatic cancer containing a 5 alpha reductase inhibitor and an antiandrogen
HU9202394D0 (en) Derivatives of cyclohexane and tetrahydro-pyrane
GB8901675D0 (en) Inhibitor of gene expression
EP0532757A4 (en) Highly sensitive assay of tissue factor and kit therefor
EP0536960A3 (en) Preparation of 2-hydroxymandelic acids and 2-hydroxybenzaldehydes
EP0411395A3 (en) Use of ace inhibitors for atherosclerosis-prophylaxis
AU1880492A (en) Novel retro-alpha-retinol derivatives and uses of retro-alpha-retinol
ZA904825B (en) Inhibition of potato-sprouting
GB2257779B (en) Lining of metallurical vessels
GB8905800D0 (en) Prevention of condensation
AU5350190A (en) Methods and compositions for the identification of patients sensitive to interferon alpha
GB9210511D0 (en) Retention of screw fixings